Relationship between Platelet PPARs, cAMP Levels, and P-Selectin Expression: Antiplatelet Activity of Natural Products

Fuentes, Eduardo; Palomo, Iván

doi:10.1155/2013/861786

Cited by 22 publications

(18 citation statements)

References 127 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the literature, it is emphasised that the main components of this cardioprotective diet are tomatoes and their products with antiplatelet function [ 24 – 27 ]. The bioactivity of tomato extract has been confirmed in both in vitro and ex vivo models [ 10 , 28 – 33 ]. The results of many experiments show dose-dependent inhibition of platelet aggregation at 8–23% after administration of extract of tomato [ 10 , 29 ].…”

Section: Discussionmentioning

confidence: 99%

Standardised tomato extract as an alternative to acetylsalicylic acid in patients with primary hypertension and high cardiovascular risk – a randomised, controlled trial

Krasińska

Osińska

Osiński

et al. 2017

aoms

View full text Add to dashboard Cite

IntroductionCardiovascular (CV) diseases remain a leading global cause of death. It has been proven that the use of acetylsalicylic acid (ASA) in secondary prevention reduces the CV risk, while the benefits of ASA in primary prevention have recently been debated. The aim of the study was to compare the antiplatelet effect of standardised tomato extract (STE) and ASA in hypertensive patients with high CV risk.Material and methodsThe study involved high-risk patients with arterial hypertension (AH) randomly assigned to one of two groups: group 1 included 33 patients receiving ASA and group 2 included 32 patients receiving STE. The platelet aggregation was determined using the VerifyNow analyser.ResultsAfter 4 weeks of ASA treatment in group 1, a statistically significant reduction in aspirin reaction units (ARU) was observed (p < 0.001). However, the obese subgroup using ASA (n = 18) did not reveal a significant decrease in ARU (p > 0.05). After 4 weeks of STE treatment in the obese subgroup (n = 14), significant declines in ARU by 8.6% (95% CI: –19.5 to –1.7%; p < 0.05) and in P2Y12 reaction units (PRU) by 7.5% (95% CI: –17.6 to 1.8%; p < 0.05) were observed.ConclusionsThe antiplatelet effect of STE in hypertensive patients may be weight dependent. The group with AH and obesity might have potentially benefitted from STE treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Standardised tomato extract as an alternative to acetylsalicylic acid in patients with primary hypertension and high cardiovascular risk – a randomised, controlled trial

Krasińska

Osińska

Osiński

et al. 2017

aoms

View full text Add to dashboard Cite

show abstract

“…However, continuous administration of ASA can induce resistance or side effects, including headache, vomiting, gastric ulceration and abdominal pain in numerous patients (10)(11)(12)(13). Therefore, studies have been investigating naturally derived antiplatelet agents with a reduced risk of side effects (14)(15)(16)(17)(18)(19).…”

Section: Introductionmentioning

confidence: 99%

Chloroform fraction of Euphorbia maculata has antiplatelet activity via suppressing thromboxane B2 formation

Kwon

Cha

Lee

et al. 2015

Molecular Medicine Reports

View full text Add to dashboard Cite

Euphorbia maculata (EM) is a traditionally used antidiarrheal, antibacterial, antifungal and antioxidant agent. However, the effects of EM on platelet activity remain to be elucidated. Therefore, the present study investigated the antiplatelet effect of various EM extract fractions on platelet aggregation in rats. The antiplatelet activity of the EM fractions on collagen or adenosine diphosphate (ADP)‑induced platelet aggregation was evaluated in vitro and ex vivo. Thromboxane B2 (TXB2) formation, rat‑tail bleeding time and coagulation time were also measured. Among the fractions, the chloroform fraction of EM (CFEM) significantly inhibited ADP‑induced platelet aggregation in vitro. Furthermore, oral administration of 50 mg/kg CFEM to rats significantly reduced ADP‑induced platelet aggregation without increasing the tail bleeding time or coagulation time. In addition, EM significantly inhibited the level of TXB2 formation in a dose‑dependent manner. These results suggest that CFEM exhibits antiplatelet activity, without causing bleeding, via the suppression of TXB2 formation. CFEM may be a type of food which has the potential for preventing cardiovascular disease.

show abstract

“…This has been of special concern in oncology due to the life-threatening consequences of lowered blood levels of drugs, and the potential for severe side effects when blood levels of a drug are increased or actions of herbal products reinforce those of conventional agents. Antiplatelet activity is common in natural products [226], and may aggravate clinical consequences in patients with thrombocytopenia due to chemotherapy or other drugs [227]. Several other examples of negative interactions are known or suspected.…”

Section: Implementation Of Broad-spectrum Research Agendamentioning

confidence: 99%

Designing a broad-spectrum integrative approach for cancer prevention and treatment

Block

Gyllenhaal

Lowe

et al. 2015

Seminars in Cancer Biology

247

191

View full text Add to dashboard Cite

Targeted therapies and the consequent adoption of “personalized” oncology have achieved notable successes in some cancers; however, significant problems remain with this approach. Many targeted therapies are highly toxic, costs are extremely high, and most patients experience relapse after a few disease-free months. Relapses arise from genetic heterogeneity in tumors, which harbor therapy-resistant immortalized cells that have adopted alternate and compensatory pathways (i.e., pathways that are not reliant upon the same mechanisms as those which have been targeted). To address these limitations, an international task force of 180 scientists was assembled to explore the concept of a low-toxicity “broad-spectrum” therapeutic approach that could simultaneously target many key pathways and mechanisms. Using cancer hallmark phenotypes and the tumor microenvironment to account for the various aspects of relevant cancer biology, interdisciplinary teams reviewed each hallmark area and nominated a wide range of high-priority targets (74 in total) that could be modified to improve patient outcomes. For these targets, corresponding low-toxicity therapeutic approaches were then suggested; many of which were phytochemicals. Proposed actions on each target and all of the approaches were further reviewed for known effects on other hallmark areas and the tumor microenvironment. Potential contrary or procarcinogenic effects were found for 3.9% of the relationships between targets and hallmarks, and mixed evidence of complementary and contrary relationships was found for 7.1%. Approximately 67% of the relationships revealed potentially complementary effects, and the remainder had no known relationship. Among the approaches, 1.1% had contrary, 2.8% had mixed and 62.1% had complementary relationships. These results suggest that a broad-spectrum approach should be feasible from a safety standpoint. This novel approach has potential to help us address disease relapse, which is a substantial and longstanding problem, so a proposed agenda for future research is offered.

show abstract

Relationship between Platelet PPARs, cAMP Levels, and P-Selectin Expression: Antiplatelet Activity of Natural Products

Cited by 22 publications

References 127 publications

Standardised tomato extract as an alternative to acetylsalicylic acid in patients with primary hypertension and high cardiovascular risk – a randomised, controlled trial

Standardised tomato extract as an alternative to acetylsalicylic acid in patients with primary hypertension and high cardiovascular risk – a randomised, controlled trial

Chloroform fraction of Euphorbia maculata has antiplatelet activity via suppressing thromboxane B2 formation

Designing a broad-spectrum integrative approach for cancer prevention and treatment

Contact Info

Product

Resources

About